🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

7 years ago we started a grant workshop for the fellows UNC Lineberger UNC-Chapel Hill We've received 20 YIA awards ASCO Conquer Cancer, the ASCO Foundation and 2 CDA awards since! Amazing testament to the caliber and grit these trainees have shown. Go Heels! 🩵 #ASCO24

Getting excited for Pelotonia 2024! Riding 50 miles this year, 100% of every dollar raised funds innovative research The James. Please consider supporting my ride! pelotonia.org/profile/TV0001

Heme Sweeps the The James Physician Recognition Celebration! 🏆 Heme Faculty earned: ✔️Physician of the Year (Don Benson) ✔️Physician Patient Champion (@kristinlynn7 Timothy Voorhees, MD, MSCR, David Bond Samuel Penza John Reneau) ✔️Physician-Scientist of the Year Congrats to our docs! 🎉

🚨CME ALERT🚨Our #SOHO2024 symposium on EBV+ PTLD  is now available On Demand! Hear expert insights from Kris Mahadeo & Timothy Voorhees, MD, MSCR on the epidemiology & burden of EBV+ PTLD, prognostic challenges & game-changing emerging treatment options. Start now & earn CE credit for free👉

5-yr f/u ZUMA-5 (axi-cel in iNHL) #ASH24: - 159 pts (most FL) with 2+ LOT - mPFS 62 mo! (FL 57 mo, MZL NR) - however, mPFS 7 mos if PR to axi-cel - mTTNT NR in all pts, mOS also NR Curative potential of axi-cel in FL and MZL! However, patients without CR still unmet need. #lymsm

Salles et al 5 yr results of POLARIX 1L RCT PolaRCHP vs RCHOP in IPI 2-5 DLBCL 5-year PFS estimates 64.2% vs 59.1% HR 0.78; 95% CI: 0.623-0.980 5-year OS 82.2% vs 79.6% not significant #ASH2024 #lymsm

Analysis of R maint problem in TRIANGLE #ASH24: 4-yr PFS with R maint vs not (not randomized): - I: 86% vs 76% - A+I: 89% vs 75% - A: 83% vs 54% More G3+ infx with R maint, heme tox basically same. Given OS findings of RCT, R maintenance is SOC in conjunction with BTKi. #lymsm

Timothy Voorhees, MD Timothy Voorhees, MD, MSCR) published "Outcomes in patients with classic #Hodgkinlymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers" in Blood Cancer Journal. 🔗pubmed.ncbi.nlm.nih.gov/40140364/

What a wonderful The James #GrandRounds presentation by Ohio State Hematology, #PIIO researcher Dr. Lapo Alinari, spotlighting Targeting #CD74 in #Hematologic_Malignancies—with a deep dive into #mantle_cell_lymphoma.

Ajay Major, MD, MBA Thanks for your contributions and highlighting our data.

I’m honored to serve as the next CEO of the @osuccc_james & look forward to joining my new Buckeye colleagues at @osuwexmed & @ohiostate to take bold steps to advance the future of oncology across Ohio & nationally. Check out my LinkedIn to learn more. go.osu.edu/C4w3

Lymphoma survivor Doug Hinkle discusses the importance of support from family, friends and cancer care teams during and after treatment. cancer.osu.edu/blog/cancer-su…

Training ride for my 50 mile ride Aug 2nd! 100% of every dollar raised goes to cancer research 🔬 Can you donate to support the ride? pelotonia.org/profile/TV0001 #Pelotonia The James Pelotonia Team Buckeye